Dr. Novack continued to work with numerous clients in providing regulatory guidance. In 2011, this included many meetings with FDA’s CDER to discuss the development of novel therapeutics.
Among the many papers and abstracts published in 2011, Dr. Novack was an author on a Phase 2a study of a novel rho kinase inhibitor for the treatment of glaucoma:
Williams RD, Novack GD, van Haarlem T, Kopczynski C for the AR-12286 Phase 2a Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 2011:152: 834-841.
Dr. Novack was selected as a member of the Glaucoma Research Society, a public interest, nonprofit scientific association of outstanding glaucoma researchers. The society provides a forum to discuss and stimulate compelling research to prevent glaucoma-related disability worldwide; the organization consists of fewer than 100 scientists whose investigations lead the field of glaucoma.